Tae-Kyung Yeo
Research Subjects
Tae-Kyung Yeo has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Hwa-Seung Yoo
East-West Cancer Center, Daejeon Korean Medicine Hospital of Daejeon University
5 shared publications - Dong-Hyeon Kim
Korean Medicine Hospital, Pusan National University, Yangsan 50612, Republic of Korea
3 shared publications - So-Jung Park
Korean Medicine Hospital, Pusan National University, Yangsan 50612, Republic of Korea
3 shared publications - Soo-Dam Kim
KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Republic of Korea
3 shared publications - Byong Chul Yoo
Institute of Biotechnology and Bioengineering, Sungkyunkwan University, Suwon 16419, Republic of Korea
2 shared publications - Jung Hyang Park
East West Cancer Center, Daejeon Korean Medicine Hospital, Daejeon University, Daejeon 34520, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8419
Modulation of Antitumor Immunity and the Tumor Microenvironment by Scutellaria barbata D. Don: A Scoping Review and Network Pharmacology Analysis
Scutellaria barbata D. Don (SBD) has been widely investigated for antitumor activity, but its immune- and tumor microenvironment (TME)-related mechanisms remain fragmented. This study synthesized preclinical evidence on SBD and contextualized the findings using network pharmacology. A scoping review was conducted according to established scoping review methodology and PRISMA-ScR guidance. Preclinical in vitro and in vivo cancer studies published between January 2016 and December 2025 were searched in PubMed, Embase, CENTRAL, and OASIS. Network pharmacology analysis was performed using TCMSP, SwissTargetPrediction, ImmPort, GeneCards, STRING, Cytoscape, MCODE, DAVID, GO, and KEGG analyses. Fifty-six preclinical studies were included. SBD extracts, fractions, polysaccharides, diterpenoids, flavonoids, and isolated constituents suppressed cancer cell proliferation, induced cell-cycle arrest, promoted apoptosis and ferroptosis, modulated autophagy, induced endoplasmic reticulum stress-associated cell death, inhibited migration, invasion, angiogenesis, and metastasis, and enhanced chemosensitivity across diverse cancer models. Immune- and TME-related effects included activation of natural killer cells and CD8+ T cells, reduction in regulatory T cells, T helper 17 cells, myeloid-derived suppressor cells, and M2-like tumor-associated macrophage polarization, modulation of cytokine and inflammatory signaling, and regulation of epithelial–mesenchymal transition, matrix remodeling, angiogenesis, and metastatic niche formation. Network pharmacology identified 32 active candidate compounds, 408 predicted targets, and 152 immune/TME-overlapping targets. Protein–protein interaction and enrichment analyses highlighted AKT1, TNF, SRC, EGFR, and BCL2 as candidate hub targets and implicated PI3K-Akt, MAPK, Ras, EGFR tyrosine kinase inhibitor resistance, and proteoglycans in cancer. SBD-derived interventions showed antitumor, immunomodulatory, and TME-remodeling activities across diverse preclinical models. The integrated findings identify recurrent biological processes and candidate molecular targets, while differences in preparation, chemical characterization, dose, and experimental design limit direct comparison across studies. This framework supports further mechanistic, pharmacokinetic, and translational evaluation of chemically characterized SBD preparations and candidate compounds.
- 21 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8419
Open AccessModulation of Antitumor Immunity and the Tumor Microenvironment by Scutellaria barbata D. Don: A Scoping Review and Network Pharmacology Analysis
Scutellaria barbata D. Don (SBD) has been widely investigated for antitumor activity, but its immune- and tumor microenvironment (TME)-related mechanisms remain fragmented. This study synthesized preclinical evidence on SBD and contextualized the findings using network pharmacology. A scoping review was conducted according to established scoping review methodology and PRISMA-ScR guidance. Preclinical in vitro and in vivo cancer studies published between January 2016 and December 2025 were searched in PubMed, Embase, CENTRAL, and OASIS. Network pharmacology analysis was performed using TCMSP, SwissTargetPrediction, ImmPort, GeneCards, STRING, Cytoscape, MCODE, DAVID, GO, and KEGG analyses. Fifty-six preclinical studies were included. SBD extracts, fractions, polysaccharides, diterpenoids, flavonoids, and isolated constituents suppressed cancer cell proliferation, induced cell-cycle arrest, promoted apoptosis and ferroptosis, modulated autophagy, induced endoplasmic reticulum stress-associated cell death, inhibited migration, invasion, angiogenesis, and metastasis, and enhanced chemosensitivity across diverse cancer models. Immune- and TME-related effects included activation of natural killer cells and CD8+ T cells, reduction in regulatory T cells, T helper 17 cells, myeloid-derived suppressor cells, and M2-like tumor-associated macrophage polarization, modulation of cytokine and inflammatory signaling, and regulation of epithelial–mesenchymal transition, matrix remodeling, angiogenesis, and metastatic niche formation. Network pharmacology identified 32 active candidate compounds, 408 predicted targets, and 152 immune/TME-overlapping targets. Protein–protein interaction and enrichment analyses highlighted AKT1, TNF, SRC, EGFR, and BCL2 as candidate hub targets and implicated PI3K-Akt, MAPK, Ras, EGFR tyrosine kinase inhibitor resistance, and proteoglycans in cancer. SBD-derived interventions showed antitumor, immunomodulatory, and TME-remodeling activities across diverse preclinical models. The integrated findings identify recurrent biological processes and candidate molecular targets, while differences in preparation, chemical characterization, dose, and experimental design limit direct comparison across studies. This framework supports further mechanistic, pharmacokinetic, and translational evaluation of chemically characterized SBD preparations and candidate compounds.
- Open Access
- 19 September 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (9) , 1492
Clinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review
Background: Thymosin alpha 1 (Tα1, thymalfasin) is a thymus-derived immunomodulatory peptide investigated as an adjunctive therapy in cancer care. Although studied across malignancies, its evidence landscape has not been systematically mapped. This scoping review characterized treatment contexts, intervention patterns, outcome domains, and safety reporting of clinical studies evaluating Tα1 in patients with cancer. Methods: PubMed, Embase, and CENTRAL were searched for clinical studies of Tα1 in patients with cancer published from January 2016 to March 2026. Eligible studies included randomized controlled trials, non-randomized studies, observational studies, and case-based reports. Data on study characteristics, cancer type, intervention features, comparators, outcomes, and adverse-event reporting were charted and synthesized descriptively. Results: Twenty-six clinical publications were included. Most were conducted in China, and retrospective observational studies and case reports predominated. Hepatobiliary, thoracic, and gastrointestinal cancers were the most frequently studied clusters. Classical Tα1 was administered mainly by subcutaneous injection, most commonly at 1.6 mg, and used primarily as an adjunct to chemotherapy, radiotherapy, chemoradiotherapy, targeted therapy, immune checkpoint inhibitors, or postoperative and supportive care. Outcomes included tumor response, survival, recurrence, immune and inflammatory markers, treatment-related toxicity, functional status, and quality of life. Several studies reported favorable clinical, immune-related, or treatment-tolerance signals, but heterogeneity limited comparability. Safety reporting was inconsistent. One case described severe multisystem immune-related toxicity during combination treatment without establishing Tα1-specific causality. Conclusions: Tα1 has been investigated mainly as an adjunctive immunomodulatory strategy in cancer care. Prospective controlled studies with standardized dosing, defined treatment contexts, consistent outcomes, and systematic harms reporting are needed.
- 19 September 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (9) , 1492
Open AccessClinical Applications and Evidence Landscape of Thymosin Alpha 1 as an Immunomodulatory Adjunct in Cancer Care: A Scoping Review
Background: Thymosin alpha 1 (Tα1, thymalfasin) is a thymus-derived immunomodulatory peptide investigated as an adjunctive therapy in cancer care. Although studied across malignancies, its evidence landscape has not been systematically mapped. This scoping review characterized treatment contexts, intervention patterns, outcome domains, and safety reporting of clinical studies evaluating Tα1 in patients with cancer. Methods: PubMed, Embase, and CENTRAL were searched for clinical studies of Tα1 in patients with cancer published from January 2016 to March 2026. Eligible studies included randomized controlled trials, non-randomized studies, observational studies, and case-based reports. Data on study characteristics, cancer type, intervention features, comparators, outcomes, and adverse-event reporting were charted and synthesized descriptively. Results: Twenty-six clinical publications were included. Most were conducted in China, and retrospective observational studies and case reports predominated. Hepatobiliary, thoracic, and gastrointestinal cancers were the most frequently studied clusters. Classical Tα1 was administered mainly by subcutaneous injection, most commonly at 1.6 mg, and used primarily as an adjunct to chemotherapy, radiotherapy, chemoradiotherapy, targeted therapy, immune checkpoint inhibitors, or postoperative and supportive care. Outcomes included tumor response, survival, recurrence, immune and inflammatory markers, treatment-related toxicity, functional status, and quality of life. Several studies reported favorable clinical, immune-related, or treatment-tolerance signals, but heterogeneity limited comparability. Safety reporting was inconsistent. One case described severe multisystem immune-related toxicity during combination treatment without establishing Tα1-specific causality. Conclusions: Tα1 has been investigated mainly as an adjunctive immunomodulatory strategy in cancer care. Prospective controlled studies with standardized dosing, defined treatment contexts, consistent outcomes, and systematic harms reporting are needed.
- Open Access
- 8 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 7996
Targeting Cancer Hallmarks with Cirsium japonicum: Molecular Mechanisms and Therapeutic Potential
Cirsium japonicum is a medicinal plant traditionally used in East Asian medicine and contains multiple bioactive constituents with potential anticancer properties. This review critically evaluates the anticancer effects of C. japonicum and its associated constituents within the Hallmarks of Cancer framework. Evidence was classified as direct plant-specific evidence, constituent-based evidence, or contextual mechanistic evidence to distinguish findings obtained using botanical preparations from those generated using purified compounds derived from other sources. Direct studies of C. japonicum extracts, flavonoid fractions, phenylpropanoid glycosides, and C. japonicum var. maackii-mediated gold nanoparticles demonstrate antitumor, cytotoxic, antiangiogenic, immunomodulatory, and ferroptosis-associated activities, although target-level validation remains limited. Among its associated constituents, pectolinarigenin has the most developed mechanistic evidence, involving RRM2–CDK1, TOP2A, STAT3, and PI3K/AKT/mTOR signaling. Apigenin, luteolin, acacetin, linarin, cirsimaritin, and pectolinarin additionally influence regulated cell death, proliferative signaling, angiogenesis, metastasis, immune regulation, metabolic vulnerability, senescence, and therapy response. However, much of this evidence relies on pathway-associated changes rather than direct target engagement or genetic validation. Furthermore, the pharmacokinetics, systemic exposure, botanical standardization, tumor selectivity, and clinical relevance of these compounds remain insufficiently characterized. Future studies should prioritize standardized preparations, quantitative exposure analysis, functional target validation, clinically relevant models, and carefully designed combination strategies. Collectively, C. japonicum provides a promising multi-hallmark framework for anticancer investigation, but substantial translational evidence is still required before its therapeutic potential can be established.
- 8 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 7996
Open AccessTargeting Cancer Hallmarks with Cirsium japonicum: Molecular Mechanisms and Therapeutic Potential
Cirsium japonicum is a medicinal plant traditionally used in East Asian medicine and contains multiple bioactive constituents with potential anticancer properties. This review critically evaluates the anticancer effects of C. japonicum and its associated constituents within the Hallmarks of Cancer framework. Evidence was classified as direct plant-specific evidence, constituent-based evidence, or contextual mechanistic evidence to distinguish findings obtained using botanical preparations from those generated using purified compounds derived from other sources. Direct studies of C. japonicum extracts, flavonoid fractions, phenylpropanoid glycosides, and C. japonicum var. maackii-mediated gold nanoparticles demonstrate antitumor, cytotoxic, antiangiogenic, immunomodulatory, and ferroptosis-associated activities, although target-level validation remains limited. Among its associated constituents, pectolinarigenin has the most developed mechanistic evidence, involving RRM2–CDK1, TOP2A, STAT3, and PI3K/AKT/mTOR signaling. Apigenin, luteolin, acacetin, linarin, cirsimaritin, and pectolinarin additionally influence regulated cell death, proliferative signaling, angiogenesis, metastasis, immune regulation, metabolic vulnerability, senescence, and therapy response. However, much of this evidence relies on pathway-associated changes rather than direct target engagement or genetic validation. Furthermore, the pharmacokinetics, systemic exposure, botanical standardization, tumor selectivity, and clinical relevance of these compounds remain insufficiently characterized. Future studies should prioritize standardized preparations, quantitative exposure analysis, functional target validation, clinically relevant models, and carefully designed combination strategies. Collectively, C. japonicum provides a promising multi-hallmark framework for anticancer investigation, but substantial translational evidence is still required before its therapeutic potential can be established.
- Open Access
- 28 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7717
From Claims to Evidence: Re-Evaluating the Molecular Pharmacology of Cirsium japonicum
Cirsium japonicum Fisch. ex DC. has long been used in traditional East Asian medicine and has attracted increasing attention because of its diverse pharmacological activities, including antioxidant, anti-inflammatory, antifibrotic, metabolic regulatory, and anticancer effects. Although numerous studies have investigated its phytochemical composition and biological activities, current evidence has largely been organized according to individual compounds or disease categories, providing limited insight into the shared molecular mechanisms underlying its pleiotropic actions. In this review, we critically re-evaluate the molecular pharmacology of C. japonicum using an evidence-oriented framework that distinguishes experimentally supported mechanisms from pharmacological associations and emerging hypotheses. Rather than accepting changes in signaling proteins or downstream biomarkers as sufficient evidence of mechanism, we assess the strength of evidence based on reproducibility, pathway-specific interventions, genetic or pharmacological validation, and direct target engagement. Current evidence indicates that nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated antioxidant responses and nuclear factor kappa B (NF-κB)-associated inflammatory responses represent the most consistently observed pathway associations, although direct molecular targets and causal pathway dependency remain insufficiently established. Evidence for AMPK/PI3K-Akt-associated metabolic regulation and TGF-β/Smad-associated antifibrotic responses is comparatively more limited. In contrast, modulation of apoptosis and autophagy is currently supported primarily by indirect or context-dependent observations. We further discuss how multiple phytochemicals converge on interconnected signaling networks regulating oxidative stress, inflammation, metabolism, tissue remodeling, and cell fate, thereby providing a systems-level explanation for the broad therapeutic potential of C. japonicum. Finally, we highlight the need for standardized phytochemical characterization, rigorous target validation, multi-omics integration, and artificial intelligence-assisted systems biology to establish causal molecular mechanisms and accelerate the translational development of evidence-based phytopharmaceuticals.
- 28 August 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7717
Open AccessFrom Claims to Evidence: Re-Evaluating the Molecular Pharmacology of Cirsium japonicum
Cirsium japonicum Fisch. ex DC. has long been used in traditional East Asian medicine and has attracted increasing attention because of its diverse pharmacological activities, including antioxidant, anti-inflammatory, antifibrotic, metabolic regulatory, and anticancer effects. Although numerous studies have investigated its phytochemical composition and biological activities, current evidence has largely been organized according to individual compounds or disease categories, providing limited insight into the shared molecular mechanisms underlying its pleiotropic actions. In this review, we critically re-evaluate the molecular pharmacology of C. japonicum using an evidence-oriented framework that distinguishes experimentally supported mechanisms from pharmacological associations and emerging hypotheses. Rather than accepting changes in signaling proteins or downstream biomarkers as sufficient evidence of mechanism, we assess the strength of evidence based on reproducibility, pathway-specific interventions, genetic or pharmacological validation, and direct target engagement. Current evidence indicates that nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated antioxidant responses and nuclear factor kappa B (NF-κB)-associated inflammatory responses represent the most consistently observed pathway associations, although direct molecular targets and causal pathway dependency remain insufficiently established. Evidence for AMPK/PI3K-Akt-associated metabolic regulation and TGF-β/Smad-associated antifibrotic responses is comparatively more limited. In contrast, modulation of apoptosis and autophagy is currently supported primarily by indirect or context-dependent observations. We further discuss how multiple phytochemicals converge on interconnected signaling networks regulating oxidative stress, inflammation, metabolism, tissue remodeling, and cell fate, thereby providing a systems-level explanation for the broad therapeutic potential of C. japonicum. Finally, we highlight the need for standardized phytochemical characterization, rigorous target validation, multi-omics integration, and artificial intelligence-assisted systems biology to establish causal molecular mechanisms and accelerate the translational development of evidence-based phytopharmaceuticals.
- Open Access
Immune and Tumor Microenvironment Mechanisms of Hedyotis diffusa Willd: A Scoping Review and Network Pharmacology Analysis
Background: The tumor microenvironment (TME) is a dynamic ecosystem that critically shapes tumor progression, immune escape, and therapeutic responses. Hedyotis diffusa Willd (HDW) has long been used in East Asian medicine for conditions associated with inflammation and malignancy, yet its immunological and microenvironmental mechanisms have not been systematically synthesized. Methods: A scoping review of preclinical studies (2016–2025) was conducted following the Arksey-O’Malley framework and PRISMA-ScR guidance to systematically map experimental evidence on the antitumor, immune-related, and TME-associated effects of HDW. To complement and interpret these heterogeneous experimental findings at a systems level, a network pharmacology analysis was performed to identify bioactive compounds, predict their putative protein targets, and assess their convergence on immune- and microenvironment-related signaling networks through protein-protein interaction and pathway enrichment analyses. Results: Fifty-nine studies met eligibility criteria, encompassing in vitro and in vivo models across diverse cancer types. Experimental evidence from preclinical models showed that HDW extracts and bioactive fractions consistently suppressed proliferation, induced apoptosis and ferroptosis, inhibited epithelial-mesenchymal transition (EMT) and angiogenesis, and enhanced cytotoxic lymphocyte activity, while attenuating tumor-associated inflammation. In parallel, in silico network analysis identified 94 intersecting immune- and TME-related targets and revealed a densely connected interaction network centered on PI3K-Akt, STAT3, EGFR, and SRC. Enrichment analyses highlighted receptor tyrosine kinase signaling, inflammatory pathways, metabolic regulation, and focal adhesion as dominant functional themes. Conclusions: HDW acts as a multi-target botanical agent that integrates direct cytotoxicity with immune activation and TME remodeling. Network-in-formed interpretation indicates that the modulation of PI3K-Akt-STAT3 signaling is a common mechanistic axis linking experimental observations.
Open AccessImmune and Tumor Microenvironment Mechanisms of Hedyotis diffusa Willd: A Scoping Review and Network Pharmacology Analysis
Background: The tumor microenvironment (TME) is a dynamic ecosystem that critically shapes tumor progression, immune escape, and therapeutic responses. Hedyotis diffusa Willd (HDW) has long been used in East Asian medicine for conditions associated with inflammation and malignancy, yet its immunological and microenvironmental mechanisms have not been systematically synthesized. Methods: A scoping review of preclinical studies (2016–2025) was conducted following the Arksey-O’Malley framework and PRISMA-ScR guidance to systematically map experimental evidence on the antitumor, immune-related, and TME-associated effects of HDW. To complement and interpret these heterogeneous experimental findings at a systems level, a network pharmacology analysis was performed to identify bioactive compounds, predict their putative protein targets, and assess their convergence on immune- and microenvironment-related signaling networks through protein-protein interaction and pathway enrichment analyses. Results: Fifty-nine studies met eligibility criteria, encompassing in vitro and in vivo models across diverse cancer types. Experimental evidence from preclinical models showed that HDW extracts and bioactive fractions consistently suppressed proliferation, induced apoptosis and ferroptosis, inhibited epithelial-mesenchymal transition (EMT) and angiogenesis, and enhanced cytotoxic lymphocyte activity, while attenuating tumor-associated inflammation. In parallel, in silico network analysis identified 94 intersecting immune- and TME-related targets and revealed a densely connected interaction network centered on PI3K-Akt, STAT3, EGFR, and SRC. Enrichment analyses highlighted receptor tyrosine kinase signaling, inflammatory pathways, metabolic regulation, and focal adhesion as dominant functional themes. Conclusions: HDW acts as a multi-target botanical agent that integrates direct cytotoxicity with immune activation and TME remodeling. Network-in-formed interpretation indicates that the modulation of PI3K-Akt-STAT3 signaling is a common mechanistic axis linking experimental observations.